Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204562 | 1.00 | BTK (0.54) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL746169 | 1.00 | BTK (0.54) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6260146 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6259821 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6260151 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL3702157 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL3702152 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL1406894 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL10343938 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| Methyl Alcohol SCHEMBL28082230 | 0.90 | BTK (0.59) | BTKEPHX2CTSKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035384-A1 | COMPOUND CONTAINING CYCLOHEXYL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12419960-B2 | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| WO-2025108406-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR, AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-5726172-A | BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA | MERCK & CO., INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0644872-B1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA GEIGY AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5516806-A | ANTITUMOR | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996002553-A2 | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1996-02-01 | — | — | WO | disclosed |
| EP-0644872-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS. | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994024093-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
| US-5166403-A | Liquid crystals | SHOWA DENKO K.K. (JP) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | BTK 2879/4885EPHX2 1734/4885CTSK 1068/4885 |
| US-12419960-B2 | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use | AR, ADRM1, CRBN | BTK 4430/4885EPHX2 2531/4885CTSK 2470/4885 |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | NLRP3, NLRP1, CASP1 | BTK 2347/4885EPHX2 586/4885CTSK 1270/4885 |
| US-20260035384-A1 | COMPOUND CONTAINING CYCLOHEXYL | CYP11B1, CYP4A11, CYP11B2 | BTK 1747/4885EPHX2 903/4885CTSK 3060/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | BTK 3955/4885EPHX2 4051/4885CTSK 2636/4885 |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ADRM1, AR, CRBN | BTK 2864/4885EPHX2 3632/4885CTSK 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.